Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo

There are still unmet medical needs for the treatment of glioblastoma (GBM), the most frequent and aggressive brain tumor worldwide. EGFRvIII, overexpressed in approximately 30% of GBM, has been regarded as a potential therapeutic target. In this study, we demonstrated that CH12, an anti-EGFRvIII mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wen, Bi, Yanyu, Kong, Juan, Zhang, Jiqin, Wang, Biao, Li, Kesang, Tian, Mi, Pan, Xiaorong, Shi, Bizhi, Gu, Jianren, Jiang, Hua, Kong, Xianming, Li, Zonghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029739/
https://www.ncbi.nlm.nih.gov/pubmed/27029073
http://dx.doi.org/10.18632/oncotarget.8407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029739/
https://www.ncbi.nlm.nih.gov/pubmed/27029073
http://dx.doi.org/10.18632/oncotarget.8407

Ejemplares similares